에 대한 최신 뉴스 Glaukos (NYSE:GKOS) 주식

Glaukos

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Glaukos Corp

Glaukos Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gkos#NYSE">GKOS</a>) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 49.7% year to date compared with the industry&#39;s 5.4% growth. The S&amp;P 500 Index has also increased 15% in the same time frame.
Glaukos, with a market capitalization of $5.91 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 1.3% for 2024, followed by 43.1% growth in 2025, and expects to maintain its strong performance in terms of revenues as well.
The company has a trailing four-quarter average negative earnings surprise of 4.74%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/72/70164.jpg?v=1990519273" /> 
Image Source: Zacks Investment Research
<h3>Key Catalysts</h3>
In 2023, Glaukos witnessed sales returning to growth after experiencing a downturn in 2022. This positive shift can be attributed to a more favorable macroeconomic climate and the introduction of a series of new products in recent quarters. The first-quarter results also reflected the strength. The company anticipates sustained robust demand in its international Glaucoma and Corneal Health product lines to support its top-line growth in the rest of 2024.
The commercial launch of the iStent infinite in 2023 has provided a significant lift to the U.S. glaucoma franchise, positioning it as a key growth catalyst in the forthcoming quarters. The company&#39;s optimistic revenue projections for 2024 indicate a positive trajectory.
Meanwhile, the new local coverage determinations, proposed in June 2023, are likely to remove certain ophthalmic goniotomy and canaloplasty procedures from coverage. This is also expected to have a positive impact on the iStent business in 2024.
Over recent quarters, GKOS has launched a suite of products, including iPrime, iAccess and iStent, which have been instrumental in boosting the company&#39;s revenues. In December, the company achieved a milestone by securing FDA approval for its latest product, iDose TR, to lower intraocular pressure in individuals with ocular hypertension or open-angle glaucoma.
These innovations are expected to continue to bolster Glaukos&#39; growth trajectory into 2024. Earlier this month, the company received a permanent Healthcare Common Procedure Coding System J-code from the U.S. Centers for Medicare and Medicaid Services that should drive patient access in the United States. This is because it will likely accelerate the billing and physician reimbursement procedures.
In May, Glaukos announced first-quarter 2024 results. The company&#39;s net sales were $85.6 million, up 16% year over year. Revenues for 2024 are estimated to be in the range of $357-$365 million, implying a year-over-year improvement of 13.4-16%.
<h3>What&#39;s Hurting GKOS?</h3>
Although Glaukos has a promising pipeline, it has faced setbacks in terms of clinical development or regulatory activities. Any potential clinical or regulatory setback can have an adverse impact on the company&#39;s share price, thereby hurting investors&#39; wealth.
The FDA denied approval to a pre-market approval application for the ab-externo device for glaucoma, MicroShunt. The company is currently evaluating alternate regulatory pathways for approval, and its commercial launch in the United States remains uncertain.
Moreover, Glaukos currently relies on a limited number of third-party suppliers, in some cases sole suppliers, to supply components for the iStent, the iStent inject models and other pipeline products. If one or more of these suppliers cease to provide the company with sufficient quantities of components or drugs in a timely manner or on acceptable terms, it would have to seek alternative sources of supply.
Glaukos&#39; production of the iStent, iStent inject models and other products in development depends on a select group of third-party suppliers, occasionally exclusive ones. If any of these suppliers fail to deliver the necessary components or drugs in a timely manner or on acceptable terms, Glaukos would be compelled to find other suppliers to maintain its production line.
<h3>Estimate Trend</h3>
The bottom-line estimate for GKOS is pegged at a loss of $2.24 per share for 2024, which narrowed 2 cents in the past 30 days. The Zacks Consensus Estimate for 2024 revenues is pinned at $362.3 million, indicating growth of 15.1% from the top line recorded in 2023.
<h3>Stocks to Consider</h3>
Some better-ranked stocks in the broader medical space that have announced quarterly results are&nbsp;DaVita&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>),&nbsp;Ecolab&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>) and&nbsp;Universal Health Services (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>).
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 29.4%.
DaVita&#39;s shares have risen 32.1% compared with the&nbsp;industry&#39;s 5% growth so far this year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%.
Ecolab&#39;s shares have rallied 18.8% against the&nbsp;industry&#39;s 21.9% decline so far this year.
Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank #2 at present. UHS has an estimated earnings growth rate of 30.5% for 2024.
UHS&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%. The company&#39;s shares have rallied 21.2% compared to the&nbsp;industry&#39;s 18.5% increase so far this year.
<a href="https://www.zacks.com/stock/news/2296487/here-s-why-you-should-retain-glaukos-gkos-stock-for-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2296487">To read this article on Zacks.com click here.</a>

Earnings

News

Markets

Analyst Ratings

Trading Ideas

GKOS

Here's Why You Should Retain Glaukos Stock for Now

Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the &quot;Exchange Agreements&quot;) with certain holders of its&nbsp;2.75%&nbsp;Convertible Senior Notes due 2027 (the &quot;Existing Convertible Notes&quot;). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of&nbsp;$230 million&nbsp;principal amount of Existing Convertible Notes for aggregate consideration consisting of a number of shares of the company&#39;s common stock, par value&nbsp;$0.001&nbsp;per share (the &quot;Common Stock&quot;), to be determined over an averaging period commencing on June 14, 2024, and cash in lieu of fractional shares and in respect of accrued interest on the Existing Convertible Notes. These exchange transactions are expected to close on or about June 25, 2024, subject to the satisfaction of customary closing conditions.

Glaukos Corporation Reveals Agreements To Exchange $230M In Principal Amount Of Its 2.75% Convertible Senior Notes Due 2027 For Common Stock; These Exchange Transactions Are Expected To Close On Or About June 25, 2024

Stifel analyst Thomas Stephan maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $110 to $130.

Price Target

Stifel Maintains Buy on Glaukos, Raises Price Target to $130

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $110 to $120.

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $120

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $114.58, a high estimate of $130.00, and a low estimate of $100.00. Witnessing a positive shift, the current average has risen by 8.92% from the previous average price target of $105.20.
<img src="https://www.benzinga.com/files/images/story/2024/1716400872_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Glaukos is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Sarcone</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Allen Gong</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Glaukos's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Glaukos's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>Discovering Glaukos: A Closer Look</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>Understanding the Numbers: Glaukos's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Glaukos's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 15.86%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -47.7%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -8.95%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Glaukos's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.36%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.85, Glaukos faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)

Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $120 to $130.

Citigroup Maintains Buy on Glaukos, Raises Price Target to $130

Jefferies analyst Michael Sarcone upgrades Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) from Hold to Buy and raises the price target from $84 to $125.

Upgrades

Jefferies Upgrades Glaukos to Buy, Raises Price Target to $125

Thursday,&nbsp;Glaukos Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) reported a first-quarter adjusted EPS loss of $(0.70), up from $(0.59) a year ago, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $(0.57)</a>.
The company reported sales of $85.6 million, up 16% Y/Y, beating the consensus of $79.6 million.
Guidance:&nbsp;Glaukos expects 2024 sales of $357 million-$365 million, compared to the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38564015/glaukos-announces-first-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $357.934 million</a>.
William Blair reports that iDose exceeded expectations during its initial&nbsp;quarter of launch,&nbsp;with the iStent franchise experiencing growth in the mid-teens, surpassing expectations as well.&nbsp;The&nbsp;growth&nbsp;was driven&nbsp;by the demand for the iStent&nbsp;infinite&nbsp;product, which&nbsp;not only&nbsp;contributed to market expansion&nbsp;but also&nbsp;captured market share in the core combo-cataract segment.&nbsp;
&#8220;Clearly,&nbsp;the glaucoma business is firing on all cylinders, and with iDose access set to improve in the second quarter and beyond, the outlook remains quite positive,&#8221; William Blair analyst said.
Throughout the first half of 2024, Glaukos has achieved significant reimbursement and commercial milestones.&nbsp;
With the full launch of iDose expected to commence, the company anticipates experiencing substantial growth in the latter half of the year.&nbsp;
Analysts suggest that as Glaukos is likely to shift its focus from surgical MIGS to a broader range of ophthalmic solutions, establishing itself as a hybrid pharma/device powerhouse, &#8220;investor interest should continue to gain momentum,&#8221; the analyst writes.
William Blair&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/GKOS/analyst-ratings" rel="noreferrer noopener">rates the stock Outperform</a>.
Other analyst reactions:
<ul>
<li>BTIG maintains Buy on Glaukos, with a price target of $112, up from $107.</li>
<li>JP Morgan maintains Glaukos with an Overweight rating&nbsp;and raises&nbsp;the price target from&nbsp;$108&nbsp;to&nbsp;$110.</li>
<li>Wells Fargo maintains Glaukos with an Overweight rating&nbsp;with&nbsp;a higher price target of $110, up from $103.</li>
<li>Needham, too, maintains with a Buy and raises the price target from&nbsp;$108&nbsp;to&nbsp;$113.</li>
<li>Truist Securities reiterates Glaukos with a Buy and raises the price target from&nbsp;$120&nbsp;to&nbsp;$125.</li>
</ul>
Price Action: GKOS shares are up 6.69% at $105.53 at last check Thursday.
Photo by Amanda Dalbjörn on Unsplash

Analyst Color

Equities

Guidance

Health Care

Reiteration

Movers

General

Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $107 to $112.

BTIG Maintains Buy on Glaukos, Raises Price Target to $112

JP Morgan analyst Allen Gong maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $108 to $110.

JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $110

WIIM

Glaukos shares are trading higher after the company reported better-than-expected Q1 sales results and issued FY24 net sales guidance above estimates. Also, multiple firms raised their respective price targets on the stock.

U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thursday.
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) rose sharply during Thursday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/CHRW/earnings">first-quarter financial results</a>.
C.H. Robinson Worldwide posted adjusted earnings of 86 cents per share, beating market estimates of 82 cents per share. The company's quarterly sales came in at $4.412 billion versus expectations of $4.269 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
C.H. Robinson Worldwide shares jumped 16.8% to $84.24 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) jumped 37.5% to $20.92 after the company reported better-than-expected first-quarter financial results.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 35.8% to $118.19 after the company announced upbeat quarterly results.</li>
<li>Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) surged 27.1% to $8.27 after the company reported mixed first-quarter financial results.</li>
<li>Gannett Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCI#NYSE">GCI</a>) rose 22.3% to $2.9519 following strong quarterly results.</li>
<li>Perdoceo Education Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) jumped 19.4% to $21.89 following upbeat results.</li>
<li>Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) rose 19.2% to $9.20 after the company reported better-than-expected first-quarter financial results.</li>
<li>Benchmark Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHE#NYSE">BHE</a>) surged 18.3% to $35.82 following better-than-expected quarterly results.</li>
<li>Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) rose 18% to $4.97 following strong quarterly results.</li>
<li>Rush Street Interactive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) shares gained 17.4% to $7.53 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) rose 15.7% to $109.62 after the company reported mixed first-quarter financial results.</li>
<li>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) climbed 15.2% to $76.93 after the company reported better-than-expected first-quarter financial results.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) rose 15% to $4.0399 after the company reported better-than-expected first-quarter adjusted EPS results.</li>
<li>Valmont Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) rose 14.4% to $237.65 after the company posted upbeat quarterly earnings and raised FY24 EPS guidance.</li>
<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) gained 13.7% to $107.81 after the company reported better-than-expected first-quarter results and raised FY24 revenue guidance.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) surged 12.8% to $76.09 after the company reported better-than-expected first-quarter results and raised its FY24 adjusted EPS outlook.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) climbed 12% to $72.08 after the company reported better-than-expected first-quarter EPS and sales.</li>
<li>Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) gained 11.7% to $56.53 after the company reported better-than-expected first-quarter financial results.</li>
<li>Tronox Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) rose 10.8% to $18.94 following strong sales.</li>
<li>Kontoor Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) gained 9.9% to $68.29 following better-than-expected quarterly results.</li>
<li>QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) climbed 8.5% to $178.02 after the company reported better-than-expected second-quarter financial results, raised its dividend and issued third-quarter guidance.</li>
<li>Belden Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) gained 8.2% to $87.95 after the company reported mixed first-quarter earnings and announced the acquisition of Precision Optical Technologies.</li>
<li>Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) rose 8.1% to $61.60 following upbeat earnings.</li>
<li>Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) gained 7.7% to $106.55 following strong sales.</li>
<li>Sealed Air Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) surged 7.7% to $34.60 after the company reported better-than-expected quarterly financial results.</li>
<li>BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) gained 7.7% to $35.39 following upbeat earnings.</li>
<li>Itron, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) rose 7.4% to $98.39 following upbeat earnings.</li>
<li>IAC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) gained 6.8% to $51.11 after it was announced the stock will join the S&amp;P SmallCap 600.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares jumped 6.5% to $118.75 following first-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38584879/apple-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Apple Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Intraday Update

ASPN

BPMC

CHRW

CVNA

ENVX

ITRI

LNTH

LUNG

MRNA

NOVA

PRDO

QCOM

TROX

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $103 to $110.

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $110

Truist Securities analyst Samuel Brodovsky reiterates Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $120 to $125.

Truist Securities Reiterates Buy on Glaukos, Raises Price Target to $125

Needham analyst David Saxon maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and raises the price target from $108 to $113.

Needham Maintains Buy on Glaukos, Raises Price Target to $113

Glaukos Sees FY24 Net Sales $357M-$365M Vs $356.669M Est.

Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.57) by 22.81 percent. The company reported quarterly sales of $85.600 million which beat the analyst consensus estimate of $79.600 million by 7.54 percent. This is a 15.83 percent increase over sales of $73.899 million the same period last year.

Earnings Beats

Earnings Misses

Glaukos Q1 2024 Adj EPS $(0.70) Misses $(0.57) Estimate, Sales $85.600M Beat $79.600M Estimate

Mizuho analyst Anthony Petrone maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Neutral and raises the price target from $85 to $100.

Mizuho Maintains Neutral on Glaukos, Raises Price Target to $100

In the last three months, 7 analysts have published ratings on Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $109.43, along with a high estimate of $120.00 and a low estimate of $103.00. Surpassing the previous average price target of $101.25, the current average has increased by 8.08%.
<img src="https://www.benzinga.com/files/images/story/2024/1712592052_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Glaukos by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Glaukos compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Glaukos's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Glaukos's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glaukos analyst ratings.</a>
<h2>About Glaukos</h2>
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
<h3>A Deep Dive into Glaukos's Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Glaukos showcased positive performance, achieving a revenue growth rate of 15.64% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Glaukos's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -44.65%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Glaukos's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -7.83%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Glaukos's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.89%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Glaukos's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.83, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Glaukos

Truist Securities analyst Samuel Brodovsky reiterates Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Buy and maintains $110 price target.

Truist Securities Reiterates Buy on Glaukos, Maintains $110 Price Target

Analyst Joanne Wuensch from Citi reiterated a Buy rating on Glaukos (GKOS – Research Report) and keeping the price target at $120.00. Joanne Wuensc...

Glaukos Corporation: Strong Financials and Promising Pipeline Merit a Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exelixis (EXEL – Research Report), Atricure (ATRC – ...

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Atricure (ATRC) and Glaukos (GKOS)

Stifel Nicolaus analyst Thomas Stephan maintained a Buy rating on Glaukos (GKOS – Research Report) today and set a price target of $110.00. The com...

Stifel Nicolaus Sticks to Their Buy Rating for Glaukos (GKOS)

Jefferies analyst Michael Sarcone upgraded the rating on Glaukos (GKOS – Research Report) to a Buy today, setting a price target of $125.00. Michae...

Buy Rating on Glaukos with Strong Growth Prospects for iDose and MIGS Market Share

Glaukos rises on upgrade to Buy at Jefferies

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genmab (GMAB – Research Report), Perspective Therape...

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Perspective Therapeutics (CATX) and Glaukos (GKOS)

Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRK – Research Report), Glaukos (GK...

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Glaukos (GKOS) and Arcus Biosciences (RCUS)

An update from Glaukos (GKOS) is now available. Glaukos Corporation's Board of Directors implemented the amended 2015 Omnibus Incentive Compensatio...

Glaukos

뉴스

에 대한 최신 뉴스 Glaukos (NYSE:GKOS) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌